Veltassa Recent News
BTIG Cuts Veltassa Estimates, Relypsa's Price Target To $35
Mizuho Downgrades Relypsa, Says Near-Term Takeout 'Unlikely'
Morgan Stanley's Berens Highlights Greater Payor Pushback For Relypsa's Veltassa
Cantor: Relypsa Sale Makes Sense
Brean Initiates Relypsa With Buy Rating, $26 Target
Cowen Analysts Happy About Relypsa-Veltassa Launch, Say These Four Things Are Coming
Relypsa Up 10% Following Encouraging Phase 1 Study Results
EXCLUSIVE: Relypsa Being Evaluated By 3-4 Potential Acquirers; Sanofi Seen As 'Natural Buyer'
Relypsa Plunges After Veltassa FDA Approval; Wedbush Says 'Misunderstanding' Creates Buying Opportunity